IL1B and epilepsy: VX-765 (Belnacasan), a caspase-1 inhibitor capable of crossing the blood–brain barrier (BBB), blocks NLRP3-mediated IL-1β and IL-18 activation and has completed Phase II trials for epilepsy with mixed efficacy (NCT01048255) [79,80].